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Significance and Impact of Study:  With increasing reports of bacterial 
resistance to antibiotics and the lack of new antibiotics being produced, 
bacteriophage therapy is becoming an attractive alternative. There has been no 
published report on the quality assurance of bacteriophage product to date. This 
is the first study on the quality assurance of a Ps. aeruginosa phage cocktail 
following pharmacopoeial requirements. The presence of bacterial endotoxin was 
found to be the key stumbling block for meeting regulatory criteria. 
 
Abstract 
The aim of this study was to determine the stability and purity of a phage cocktail 
to be delivered by nebulisation. A cocktail of three phages active against 
Pseudomonas aeruginosa isolates from cystic fibrosis patients was developed for 
a potential nebulised formulation. The individual phages were examined for their 
retention of activity over time, while the phage cocktail was analysed for bacterial 
contaminant and endotoxin level according to regulatory requirements for 
nebulised products. The phage cocktail was nebulised using a Porta-neb 
nebuliser connected to an Anderson cascade impactor. The three phages 
retained activity over a period of 180 days storage at room temperature and at 
4°C. Nebulised phages were recovered in the lower stages of the cascade 
impactor indicative of potential delivery deep into the lungs. The phage cocktail 
met bacterial limits but the endotoxin levels measured with the Limulus 
amoebocyte lysate (LAL) test remained considerably in excess of acceptable 
levels even following purification.  These findings suggest that nebulisation of 
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phage is a viable delivery option; although there is a need for appropriate 
depyrogenation strategies to remove bacterial endotoxins from phage based 
preparations in order to meet regulatory requirements. 
 
Introduction 
With renewed interest in the use of phage to treat bacterial infection, attention is 
drawn to the production of phage formulations for clinical use and the regulatory 
requirements that such a product must satisfy. These requirements vary 
depending on the intended application and route of administration with topical 
applications requiring less stringent microbiological controls than, for example, 
intravenous injections (Anon., 2013a,b).  In this regard, many of the commercially 
produced phage products currently undergoing trials are of a topical nature 
(Wright et al., 2009). There is currently a paucity of information on the quality of 
phage products for clinical applications. This paper aims to investigate the 
alignment of a prototype nebulised phage formulation with selected 
pharmacopoeial requirements. 
 
 
Results and Discussion 
The phage cocktail described in this study met the British Pharmacopoeial 
bacterial limit test for non-sterile manufactured products (Anon., 2013c). All 
phage cocktails showed an absence of microbial contamination according to 
pharmacopeial standards (data not shown). In addition, there was no significant 
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difference in viable phage at both room temperature and 4oC (P≥0.05) for all 3 
phages (Fig. 1). There was no statistically significant difference in phage viability 
due to storage conditions (P≥0.05) with the exception of LP-M 10 at 180 days 
storage (P≤0.003).  In general phage LP-M 10 was most susceptible to loss of 
viability following storage (approx. 1log10 reduction in phage concentration at 4oC; 
Figure 1c) and GL-1 least susceptible to loss following storage (approx. 0.5log10 
at 4oC reduction in phage titre; Figure 1a) over a period of six months. While the 
current crude preparation demonstrated stability over a period of six months, final 
commercially available preparations may require the addition of stabilizing 
agents.  These formulations would subsequently require BP or EP based 
preservative efficacy testing in order to demonstrate long term stability.  Due to 
the enhanced nature of pharmacopeial compliance for some products, many of 
the phage preparations currently undergoing clinical trials (Wright et al., 2009) or 
currently licensed for use (e.g. ListShieldTM, Intralytix, USA) are for topical use or 
for applications for the food industry.  For approval for the use in the food 
industry, the ListshieldTM product has demonstrated that the phage cocktail used 
is at little or no risk of causing adverse side effects and that no potentially 
pathogenic sequences for Listeria reside within the phage genome (Food and 
Drug Administration, 2006; 
http://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/u
cm154675.htm, accessed 07/05/2013). The current investigation demonstrated 
the ease with which phage preparations could meet the basic microbiological 
requirements for non-sterile topical applications, however for more complex 
 5 
applications, further work including the sequencing of the phage genome would 
need to be undertaken.  
 
This study demonstrated that a phage cocktail can be successfully nebulised with 
very little loss of infectivity. There was no significant difference (P=0.848) 
between the total number of phage at the start of the nebulisation process and 
the total number of phage recovered after nebulisation. In addition, the deposition 
pattern of the phage throughout the 7 stage cascade impactor indicated that most 
of the phages would reach the throat and upper airways (corresponding to stages 
0-3 of the cascade impactor), while a quarter would reach secondary bronchi and 
alveoli (represented by deposition between stages 4 and 7). Indeed 99.2% (± 
4.2%) of phages were recovered by stage 7 of the cascade impactor; 75% of 
phages were deposited between stages 0 and 3, and the remaining phages 
between stage 4 and 7 (results not shown). 
 
The production of endotoxin from the lysis of the Ps. aeruginosa strains used 
here represents a major hurdle for the further development of non-topical phage 
products and notably for nebulised applications. When endotoxin levels were 
assessed using the Endosafe PTS LAL kinetic assay, the phage cocktail showed 
high levels of endotoxin (>5 Log10 EU ml-1; Table 1).  Following purification via 
passage through the Endotrap system, there was a small drop in endotoxin levels 
(approximately 0.2 Log10 EU ml-1) but this was not significant when compared to 
the “unpurified” phage cocktails (P=0.327).  This level of endotoxin far exceeds 
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the pharmacopeial required levels (<0.2 EU ml-1) and as such would fail quality 
assurance. To note, because of the level of endotoxin present in the phage 
cocktail, the LAL assay used here required the dilution of samples that were 
above the detection threshold of the cartridge (1 EU ml-1), requiring the 
extrapolation of endotoxin levels from a positive result. Furthermore, the activity 
assessment of both “purified” and “unpurified” phage preparations on the 
Bioscreen C analyser shows a small but not significant decrease (P≥0.05) in the 
level of activity of the phages at 8 and 20 h (Table 1).  This is most probably 
caused by the small but non-significant reduction (P=0.124) in the phage number 
following passage through the Endotrap system.  Although the use of an overlay 
based propagation method has been used in the current investigation this would 
not be appropriate for large scale manufacture, due to the relatively low 
throughput. 
The determination of endotoxin levels in phage preparations have previously only 
been measured with the rabbit pyrogenicity assay (Merabishvili et al., 2009). In 
our study, the pharmacopeial “gold standard” LAL assay (Anon, 2013d,e) has 
been used to quantify endotoxin levels in both “non-purified” and “purified” phage 
cocktails demonstrating unacceptably high endotoxin levels.  The LAL assay not 
only provides quantitative data with regards to the total endotoxin levels within 
samples, but also is more sensitive than animal models (Ong et al., 2006). The 
purification of phage preparations with the Endotrap Blue system has previously 
been demonstrated to be effective at reducing endotoxin levels in phage 
preparations (Merabishvili et al., 2009).   In the current investigation endotoxin 
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levels were not significantly altered by passage through the Endotrap Blue 
system. The saturation of the column with the high level of endotoxin present in 
our sample could explain the overall low reduction in the endotoxin level, 
although this possibility was not tested at the time of the experiment. For 
laboratory scale preparation, caesium chloride gradients and PEG precipitations 
have been demonstrated to purify phages (Gill and Hyman, 2010) although this 
may be impractical for manufacturing processes due to associated costs with 
large scale centrifugation and the requirement to know buoyant densities of 
phages particularly for caesium chloride gradients. 
 
This investigation illustrated the range of microbial quality control matters that 
should be addressed in the formulation of phage based products, in particular the 
endotoxin levels within phage preparations.  Although the nebulised phage 
cocktail was stable over a 6-month period showing no bacterial contamination, 
the level of endotoxin remained high. Reducing the endotoxin level is the limiting 
factor in this study, (practical and financial), to produce an appropriate nebulised 
phage product. 
 
Materials and Methods 
Preparation of bacterial and bacteriophage inocula 
Ps. aeruginosa strain PAO1 (Cooper et al., 2011) was routinely cultured for 24 h 
in 10 ml of tryptone soya broth (TSB, Oxoid, UK) at 37oC prior to use and 
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standardised to contain between 1-5 x 108 CFU ml-1 by reference to optical 
density measurements at 600nm.   
 
Phage cocktail preparation 
Phage GL-1, GL-12.5 and LP-M10 described by Cooper et al. (2011) were used. 
Individual phage stock was prepared by using Ps. aeruginosa PAO1 as host 
using the classical agar overlay method (Adams, 1959).  In brief, 10µl of a 
bacterial suspension (approx. 108 CFU ml-1) was mixed with 10 µl phage stock 
suspension and added to 5 ml of overlay agar (26 g/l TSA) containing 50 µmol l-1 
CaCl2. Phages were diluted 1:10 in PBS and enumerated using the overlay agar 
method as described above. Phages were harvested as described previously by 
Cooper et al. (2011). A cocktail containing equal amounts of phage GL-1, GL-12.5 
and LP-M10 (approx. 1011 PFU ml-1) was prepared in 0.9% (w/v) saline containing 
50 µmol l-1 CaCl2.   
 
Removal of endotoxins from the phage cocktail 
Endotoxins were removed from the phage cocktail preparation using the 
Endotrap Blue Chromatography system (Hyglos, Germany) as follows: the 
prepacked column was drained and regenerated using the regeneration buffer 
supplied by the manufacturer.  Following regeneration the column was washed 
twice in 0.9% (w/v) saline containing 50 µmol l-1 CaCl2 (equilibration buffer).  The 
phage cocktail was added and flushed through with the equilibration buffer. The 
column was then washed and regenerated prior to the addition of the next 
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sample.  When not in use the column was stored in 0.2% (w/v) sodium azide at 
4oC. Samples of purified phage cocktail were assessed for their endotoxin 
content within 1 h.  The activity of bacteriophage cocktails was assessed by a 
Bioscreen C based assay as previously described by Cooper et al. (2011) for lytic 
activity compared to untreated growth at 8 and 20h post phage addition as well 
as potential regrowth from bacterial survivors. 
 
Nebulisation 
Ten ml of the phage cocktail was transferred to the Ventstream drug chamber of 
a Porta-neb nebuliser (Respironics Respiratory Drug Delivery Ltd., Chichester, 
UK).  The nebuliser was connected to an Anderson cascade impactor (Pandey et 
al., 2003) and air was drawn through the impactor at a rate of approximately 28 L 
min-1. The phage suspension was then nebulised for 10 min after which the 
remaining phages in the Ventstream drug chamber were recovered and 
enumerated by the agar overlay method (Cooper et al., 2011) using Ps. 
aeruginosa PAO1 as a host.  
Steel sampling plates from each impactor stage were removed aseptically from 
the cascade impactor and transferred to sterile petri dishes.  Ten ml sterile PBS 
was added to each petri dish, and the dishes shaken at 150 RPM for 15 min. The 
PBS wash fluid was then pipetted into a sterile centrifuge tube, vortexed and the 
phage enumerated by the agar overlay method (Cooper et al., 2011) using Ps. 
aeruginosa PAO1 as a host. 
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Phage stability 
Ps. aeruginosa phage suspensions of GL-1, GL-12.5 and LP-M10 were prepared in 
phosphate buffered saline (PBS) using the agar overlay method (Cooper et al., 
2011).  Following an initial quantification of phage viability, triplicate samples 
were stored at 4 ± 1oC or room temperature (21 ± 1oC).  Phage viability was then 
measured by the agar overlay method using Ps. aeruginosa PAO1 as a host after 
7, 30, 60, 90 and 180 days storage. 
 
Endotoxin content 
All glassware and containers were depyrogenated by dry heat sterilization at 
200oC for 1 h (Anon., 2013f).  Buffers and reagents were prepared in pyrogen-
free cell culture grade water (Sigma Aldrich, Dorset, UK).  
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The endotoxin level in the phage cocktail was determined with a Limulus 
amoebocyte lysate (LAL) kinetic chromogenic method using the Endosafe®-PTS 
(Charles River Laboratories International Inc., MA, USA) according to 
manufacturer’s instructions (Charles River Laboratories International Inc., MA, 
USA) with a PTS testing cartridge (0.05 endotoxin units per millilitre (EU ml-1); 
Charles River Laboratories International Inc., MA, USA). Measurements were 
performed in triplicate.  A negative control consisted of 0.9% (w/v) saline 
prepared in pyrogen-free cell culture grade water.  All samples were diluted in 
LAL reagent grade water (Charles River Laboratories International Inc., MA, 
USA).  
 
Determination of the bacterial content of the phage product 
The level of microbial contamination in the phage cocktails before and after 
passaging through the Endotrap Blue Chromatography system was assessed in 
accordance with Pharmacopoeial requirements for non-sterile respiratory 
products (Anon. 2013c,g) as follows: 
 
Total aerobic viable count: one ml of the phage cocktail was used to inoculate 20 
ml of molten tryptone soya agar (TSA, Oxoid, UK) or 20 ml of Sabouraud 
dextrose agar (SAB; Oxoid, UK).  This was repeated for triplicate plates.  TSA 
plates were incubated at 37oC for 5 days and SAB plates were incubated at 30oC 
for 5 days.  Plates were checked for growth every 24 h. 
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Absence of Ps. aeruginosa: one ml of phage cocktail was added to 100 ml TSB 
and incubated at 37oC for 48 h.  After incubation, a sample was streaked onto 
Cetrimide agar (Oxoid, UK) and incubated at 41-43oC for 24 h. Ps. aeruginosa, if 
present, appeared as blue/green colonies. 
 
Absence of Staphylococcus aureus: one ml phage cocktail was added to 100 mL 
TSB and incubated at 37oC for 48 h.  After incubation, a sample was streaked 
onto Baird-Parker Agar (Oxoid, UK) and incubated at 37oC for 72 h. S. aureus, if 
present, appeared as black colonies with a clear halo. 
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Figure 1: Stability of phage cocktail components over a period of 180 days. 
a, GL-1; b, GL-1 2.5 and c, LP-M 10. ■, Room temperature, ■, 4oC.  Data shown 
are the mean of 3 replicates ± SD. 
 
 
a 
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c 
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Table 1: Activity of Ps. aeruginosa cocktails following purification on the 
Endotrap Blue system against Ps. aeruginosa strain PAO1.  Data shown are 
the mean of 3 replicates (±SD).  1: Time taken to increase OD420-580nm by 0.1 
above the original OD420-580nm. 
 
 
Recovery - 
Log10 PFU/ml 
(SD) 
Bioscreen C Assay Endotoxin 
Levels -Log10 
EU/ml (SD) 
Log10 Reduction (SD) Time1 
(min) 8 h 20 h 
“unpurified” Preparation 
11.02 (0.07) 1.85 (0.11) 1.84  (0.19) >1200 6.05(0.06) 
“Purified” Preparation 
10.81 (0.18) 1.78 (0.12) 1.77 (0.29) >1200 5.81(0.37) 
 
 
